COVID-19: A review of drugs and therapies for children

Patel Zeeshan Jameel1, Amar M Taksande1

Sri Lanka Journal of Child Health, 2020; 49(3): 210-217
DOI: http://dx.doi.org/10.4038/sljch.v49i3.9136

(Key words: Paediatrics, COVID-19, coronavirus, chloroquine, azithromycin, vitamin supplementation, interferons)

Introduction

The World Health Organisation (WHO) has declared the disease as Corona Virus Disease (COVID-19) due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Coronavirus infection was restricted to animals but gained importance in medicine as it acted as the aetiological factor responsible for the SARS epidemic in 2002 in the Guangdong province of China1. WHO reported its spread to over 26 countries, causing infections in 8096 individuals and 774 deaths2. This group of viruses caused another outbreak in 2012 as Middle Eastern Respiratory Syndrome (MERS)3. Since December 2019, a strain of novel coronavirus has wreaked havoc in the Hubei province of China and has caused severe pneumonia4. On March 11, the WHO declared it a ‘pandemic’. More than 1.5 million cases of COVID 19 have been reported with a mortality of over 85,000 across 212 countries5. The largest study on children with COVID 19 to date includes an analysis of 2143 children documented from 16th of January, 2020 to 8th of February, 2020. This study showed that only 1 child had died while 5.9% were critical or had severe pneumonia, the majority having mild to moderate illness6. Although pneumonia remains the chief cause of death among the under 5 year age category, the features of COVID-19 pneumonia were relatively milder compared to pneumonia of other aetiologies and the prognosis was better with deaths being extremely rare6-8.

Clinical presentation in infants and children

Since the outbreak of the pandemic, 9 infants were reported to be positive till 6th February, 2020 in China with the youngest being 1 month old and the oldest being 11 months old9. In older children, clinical presentation varied from asymptomatic to symptoms of mild upper respiratory tract infection in the majority6, 22% manifesting with pneumonia, and some children having gastrointestinal symptoms such as abdominal pain, nausea, vomiting and diarrhoea10. The first paediatric case of severe pneumonia in China due to SARS-CoV2 requiring mechanical ventilation was reported by Chen F, et al11. Thus SARS-CoV2 can cause a severe form of pneumonia in the paediatric age group and there is a dire need for efficient management strategies. To date, no definitive treatment strategy has proven efficacious for SARS-CoV2 infection. Table 1 lists all possible management strategies in children.

Triage

A pre-defined, devoted area for triage of patients is essential for all children suspected of having COVID-19. Use of Personal Protective Equipment (PPE) is mandatory for the attending paediatrician. It must be ensured that the child and accompanying parents/relatives are using a 3-ply surgical mask12.

Respiratory support

Oxygen support is required in a child with oxygen saturation (SpO2) less than 90% and/or with signs of respiratory distress13. The British Paediatric Respiratory Society (BPRS) has advised that hypoxic children should initially receive low flow nasal cannula (LFNC) oxygen rather than high flow nasal cannula (HFNC) oxygen as HFNC is associated with an increased risk of aerosol spread14. HFNC may be the next step if the child continues to be hypoxic14. Improvement is indicated by reduced heart and respiratory rates by 10-20%, reduced fraction of inspired oxygen (FiO2) requirements to less than half and improved SpO213.

Both the European Society of Intensive Care Medicine and the American Association for Respiratory Care have advised against usage of non-invasive ventilation (NIV) in acute respiratory failure in H1N1 influenza as it is a high risk procedure which should be cautiously used due to the high probability of spread of infection13,15.
Bubble continuous positive airway pressure (Bubble CPAP) is an alternative procedure which may be used for newborns and children with hypoxia when both NIV and mechanical ventilation are not available\textsuperscript{13}. Lung protective mechanical ventilation is a recommended strategy for treatment of acute hypoxic respiratory failure\textsuperscript{16}.

### Table 1: Management strategies of possible implication in paediatrics

- **Triage**
- **Respiratory support**
  - Low flow nasal cannula (LFNC)
  - High flow nasal cannula (HFNC) / Heated high flow nasal cannula (HHFNC)
  - Non-invasive ventilation (NIV)
  - Bubble continuous positive airway pressure (Bubble CPAP)
  - Mechanical ventilation (MV)
- **Nutritional supplementation**
  - Vitamin B complex
  - Vitamin C
  - Zinc
- **Immunotherapy**
  - Interferons
  - Convalescent plasma or intravenous immunoglobulin (IVIg)
- **\textit{CoV} specific therapy**
  - \textit{CoV} protease inhibitors like Cinanserin
  - Spike(S) protein ACE 2 Blockers like Griffithsin, ACE2 binding Ab or peptides
- **Chloroquine / Hydroxychloroquine (CQ/HCQ)**
- **Antiviral therapy**
  - Ribavirin
  - Lopinavir / Ritonavir
  - Remedesivir
- **Antibiotics**
  - Azithromycin
  - Teicoplanin
- **Anti-parasitic drugs**
  - Ivermectin

### Nutritional supplementation
Riboflavin supplementation has been reported to effectively scale down the titres of MERS-CoV in the human plasma products\textsuperscript{17}. Treatment with nicotinamide was able to significantly repress neutrophil infiltration into lungs during ventilator induced lung injury but had no effect on cytokine production or protein leakage and was also found to paradoxically lead to hypoxaemia\textsuperscript{18}. Pyridoxine plays a vital role in antibody production and immune system regulation\textsuperscript{19}. Thus, B complex vitamins are a valuable adjunct in COVID-19 therapy.

Five trials found preventive or therapeutic benefits of vitamin C against pneumonia with the overall quality of the studies being good\textsuperscript{20}. Thus, Vitamin C supplementation is a potential therapy in the treatment of viral pneumonias. Because of this, a triple blinded randomised controlled trial (RCT) is being carried out by Peng \textit{et al}\textsuperscript{21} evaluating the role of intravenous ascorbic acid for treatment of severe pneumonia due to COVID-19. Results of this trial are awaited.

Velthuis \textit{et al}\textsuperscript{22} determined in their study that zinc and pyrithione when administered at low concentration inhibited the replication of SARS-CoV in Vero-E6 cells by RdRp template binding and inhibition of its elongation. Therefore, zinc supplementation may be a useful treatment for this novel coronavirus.

### Immunotherapy
Interferons (IFNs) restrict virus replication before adaptive immune responses develop\textsuperscript{23}. Ian Hall, a molecular medicine professor at Nottingham University stated, “The idea behind the trial is that by giving more of this molecule to the lung, it could help reduce the severity of infection with COVID 19, especially in those people who have reduced immune responses to the virus. If the trial shows that interferon beta is a useful treatment for COVID 19, it would provide a way to reduce the severity of disease and potentially reduce death rates”\textsuperscript{24}. Ströher \textit{et al}\textsuperscript{25} found that the SARS-CoV is inhibited in tissue culture by IFN-α2b at concentrations of ≥1000IU/ml. Another study concluded that early intervention with the use of exogenous IFNs only or along with direct antivirals prior to complete subversion of the host’s immune
response may provide a viable treatment option. In an observational cohort study comprising 36 children, an aerosolized form of interferon alpha was used for all patients with no adverse outcomes or mortality. A study by Chen et al. found that both leucocytic IFNα and IFNβ1a were more active and ribavirin was determined to have highly synergistic action with either of the two IFNs. The study concluded that ribavirin combined with either IFN must be considered for SARS therapy.

On the basis of experience of using INFα as well as clinical research in the treatment of bronchiolitis, viral pneumonia, acute upper respiratory infection and SARS in childhood, Shen et al. recommends the use of IFNs in the following dosages:

- INFα nebulization: INFα 200,000-400,000 IU/kg in 2ml sterile water, twice a day for 5-7 days.
- INFα2b spray for high risk population with close contact with suspected SARS-CoV2 infected patients or those in early phase with only upper respiratory tract symptoms. Use 1-2 sprays in each nostril with 8-10 sprays in oropharynx, 1-2 hourly, 8-10 sprays/day for 5-7 days (Dose of INFα2b per injection – 8000IU).

Convalescent plasma or immunoglobulins can be considered in SARS patients who continue to deteriorate in spite of treatment. Furthermore, numerous studies suggest that testing the efficacy of therapy with convalescent plasma or SARS specific hyper-immune immunoglobulin in the early phase of SARS could be rewarding. Hung et al. showed a substantial decrease in the relative risk of death in patients being treated with convalescent plasma during the H1N1 influenza A pandemic in 2009. The WHO recommended use of convalescent plasma from recovered patients as an empirical therapy in the 2014 Ebola outbreak. The meta-analysis by Mair-Jenkins et al. concluded that the use of convalescent plasma may decrease mortality and appears to be safe. However, it also concluded that this therapy should be studied with a well-designed clinical trial for therapy of CoV infections. Shen et al. treated 5 critically ill adults with COVID-19 and ARDS with convalescent therapy containing neutralizing antibody and results showed decreasing Sequential Organ Failure Assessment Score (SOFA) in all 5 of them, decreased oxygen demand and weaning of 3 adults from ventilator within 14 days with all 5 surviving the serious illness. Thus, literature shows that convalescent plasma from recovered patients is a management strategy with some potential at this time but it is yet to be tried in the paediatric population.

Intravenous immunoglobulins (IVIg) may be used in severe cases or critically ill patients but requires further validation. The recommended dose in children is 1g/kg/day for 2 days or 400mg/kg/day for 5 days. In a single centre observational study by Dan Sun et al., immunoglobulin therapy was administered to 4 patients with 2 children getting discharged while the other 2 were still in the intensive care unit at the time of publication of the study.

CoV specific therapy

CoV protease inhibitors

Cinanserin is a drug well-known for its antagonistic action on serotonin receptor. In the study by Chen et al., cinanserin inhibited the 3-chymotrypsin-like protease of SARS-CoV and also inhibited replication of SARS-CoV. In a study by Parks JY, et al, diarylheptanoids inhibited the papain-like protease of SARS-CoV.

Spire (S) protein ACE 2 blockers

Griffithsin, a lectin, binds to oligosaccharides present on the surface of some viral glycoproteins, including SARS-CoV spike glycoprotein and HIV glycoprotein 120. ACE2 is a receptor for SARS-CoV virus and mediates its entry into the cell by binding with S protein. Blocking the binding of S protein to ACE2 is an important therapeutic option which could be used for treatment in the form of mAb. Sui et al. have developed an anti-S1 human monoclonal antibody 80R which neutralizes SARS-CoV infection with a strong nanomolar affinity and also efficiently inhibits formation of syncytia by receptor binding blockade. The data in this in vitro study also suggested that the monoclonal antibody may be further developed and tested in in vivo animal studies to determine its clinical utility as a potent inhibitor of viral entry for use in prophylaxis and treatment of SARS.

CoV specific treatment is yet to be evaluated in the paediatric population.

Chloroquine/Hydroxychloroquine (CQ/HCQ)

Wang et al. tested 5 FDA approved drugs in vitro to reduce the viral infection Vero E6 cells and found CQ to be effective against 2019-nCov(EC50=6.90μM). Numerous trials have been started already evaluating the role of CQ in COVID-19 infection. Interim results of these trials may be available by April 2020. An expert consensus comprising multicentre collaboration group of the Department of Science and Technology of Guangdong province and Health Commission of Guangdong province have published a paper regarding the use of CQ phosphate. Although, there was no information on the methodology utilized to achieve this consensus but based on multiple in vitro studies and clinical experience which are yet
to be published, the panel recommends CQ supplementation may be useful as preventive measures as well as in asymptomatic patients. Interferons, SARS-CoV-2 specific antivirals, HCQ/CQ, Azithromycin and Ivermectin present the best available therapeutic agents for symptomatic children. However, a series of clinical trials are required at the earliest to evaluate their efficacy and safety in the paediatric population.

References

1. Xu RH, He JF, Evans MR, Peng GW, Field HE, Yu DW, et al. Epidemiologic clues to SARS origin in China. Emerging Infectious Diseases 2004; 10(6):1030–7. https://doi.org/10.3201/eid1006.030852 PMid: 15207054 PMCid: PMC3323155

2. WHO guidelines for the global surveillance of severe acute respiratory syndrome (SARS). Updated recommendations, October 2004. WHO/CDS/CSR/ARO/2004.1

3. Cauchemez S, Fraser C, Van Kerkhove MD, Donnelly CA, Riley S, Rambaut A, et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infectious Diseases 2014; 14(1):50–6. https://doi.org/10.1016/S14733099(13)70304-9

4. Wu P, Hao X, Lau EHY, Wong JY, Leung KSM, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Eurosurveillance 2020; 25(3): Jan 23. https://doi.org/10.2807/15607917.ES.2020.25.3.2000044 PMid: 31992388 PCid: PMC6988272

5. WHO COVID-19 Dashboard [Internet]. [cited 2020 Apr 10]. Available from: https://who.sprinklr.com/

6. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020 March 16. Pi: e20200702 https://doi.org/10.1542/peds.2020-0702 PMid: 32179660

7. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatrica 2020; 23 March. https://doi.org/10.1111/apa.15270
8. Caselli D, Aricò M. 2019-nCoV: Polite with children! *Pediatric Reports* 2020; 12(1): Feb 11. https://doi.org/10.4081/pr.2020.8495 PMid: 32153742 PMcid: PMC7036705

9. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel coronavirus infection in hospitalized infants under 1 year of age in China. *Journal of the American Medical Association* 2020; 323(13):1313–4. https://doi.org/10.1001/jama.2020.2131 PMid: 32058570

10. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infectious Disease* 2020; Mar 25 https://doi.org/10.1016/S14733099(20)30198-5

11. Chen F, Liu ZS, Zhang FR, Xiong RH, Chen Y, Cheng XF, et al. First case of severe childhood novel coronavirus pneumonia in China. *Zhonghua Er Ke Za Zhi* 2020; 58:E005.

12. Ravikumar N, Nallasamy K, Bansal A, Angurana SK, Basavaraja GV, Sundaram M, et al. Novel Coronavirus 2019 (2019-nCoV) Infection: Part I - Preparedness and management in the paediatric intensive care unit in resource-limited settings. *Indian Pediatrics* 2020; 57(4):1–18. https://doi.org/10.1007/s13312-020-1785-y PMcid: PMC7182738

13. Sundaram M, Ravikumar N, Bansal A, Nallasamy K, Basavaraja GV, Lodha R. Novel Coronavirus 2019 (2019-nCoV) Infection: Part II - Respiratory support in the paediatric intensive care unit in resource-limited settings. *Indian Pediatrics* 2020; 57(4):1–15.

14. COVID-19 - Clinical management of children admitted to hospital with suspected COVID-19. British Paediatric Respiratory Society and the British Paediatric Allergy, Immunity and Infection Group; 17 Apr 2020.

15. Nava S, Schreiber A, Domenighetti G. Noninvasive ventilation for patients with acute lung injury or acute respiratory distress syndrome. *Respiratory Care* 2011; 56(10):1583–8. https://doi.org/10.4187/respcare.01209 PMid: 2208399

16. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Medicine* 2020 Mar 28. https://doi.org/10.1007/s00134-02006022-5

17. Keil SD, Bowen R, Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. *Transfusion (Paris)* 2016; 56(12): 2948–52. https://doi.org/10.1111/trf.13860 PMid: 27805261 PMcid: PMC7169765

18. Jones HD, Yoo J, Crother TR, Kyme P, Ben-Shlomo A, Khafai R, et al. Nicotinamide exacerbates hypoxaemia in ventilator-induced lung injury independent of neutrophil infiltration. *PloS One* 2015; 10(4): e0123460. https://doi.org/10.1371/journal.pone.0123460 PMid: 25875775 PMcid: PMC4395431

19. Mikkelsen K, Apostolopoulos V. Vitamin B1, B2, B3, B5, and B6 and the immune system. In: Mahmoudi M, Rezaei N, editors. Nutrition and Immunity. Cham: Springer International Publishing; 2019 p. 115–25. https://doi.org/10.1007/978-3-030-16073-9_7

20. Hemiš H, Louhiala P. Vitamin C for preventing and treating pneumonia. *Cochrane Database Systematic Reviews* 2007; 24(1): CD005532. https://doi.org/10.1002/14651858.CD005532.pub2 PMcid: PMC2099400

21. Vitamin C Infusion for the treatment of Severe 2019-nCoV infected pneumonia - ClinicalTrials.gov [Internet]. [cited 2020 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT04264533
22. te Velthuis AJW, van den Worm SHE, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn2+ inhibits Coronavirus and Arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLOS Pathogens 2010; 6(11):e1001176. https://doi.org/10.1371/journal.ppat.1001176 PMid: 21079686 PMCid: PMC2973827

23. Smith GL, Talbot-Cooper C, Lu Y. Chapter Fourteen - How does vaccinia virus interfere with interferon? In: Kielian M, Mettenleiter TC, Roossinck MJ, editors. Advances in Virus Research. Academic Press; 2018. p. 355–78. https://doi.org/10.1016/bs.aivir.2018.01.003 PMid: 29551142

24. Ströher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. Journal of Infectious Diseases 2004; 189(7):1164–7. https://doi.org/10.1086/382597 PMid: 15031783 PMCid: PMC7109643

25. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. Journal of General Virology 2014; 95(Pt 3):571–7. https://doi.org/10.1099/vir.0.061911-0 PMid: 24323636 PMCid: PMC3929173

27. Chen F, Chan KH, Jiang Y, Kao RYT, Lu HT, Fan KW, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. Journal of Clinical Virology 2004; 31(1):69–75. https://doi.org/10.1016/j.jcv.2004.03.003 PMid: 15288617 PMCid: PMC7128415

28. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World Journal of Pediatrics 2020; Feb 7. https://doi.org/10.1007/s12519-02000344-6

29. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infectious Diseases 2020; 20(4):398–400. https://doi.org/10.1016/S14733099(20)30141-9

30. Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology and Infectious Diseases 2005; 24(1):44–6. https://doi.org/10.1007/s10096-004-1271-9 PMid: 15616839 PMCid: PMC7088355

31. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinical Infectious Diseases 2011; 52(4):447–56. https://doi.org/10.1093/cid/ciq106 PMid: 21248066

32. WHO. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease. September 2014. WHO/HIS/SDS/2014.8

33. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: A systematic review and exploratory meta-analysis. Journal of Infectious Disease 2015; 211(1):80–90. https://doi.org/10.1093/infdis/jiu396 PMid: 25030060 PMCid: PMC4264590

34. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Journal of the American Medical Association 2020; 323(16):1582-9. https://doi.org/10.1001/jama.2020.4783 PMid: 32219428

35. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, et al. Diagnosis and treatment recommendations for paediatric respiratory infection caused by the 2019 novel coronavirus. World Journal of Pediatrics 2020; 16:240-6.
36. Sun D, Li H, Lu X-X, Xiao H, Ren J, Zhang F-R, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. *World Journal of Pediatrics*. 2020; Mar 19. https://doi.org/10.1007/s12519-020-00354-4 PMCID: PMC7091225

37. Chen L, Gui C, Luo X, Yang Q, Günther S, Scandella E, et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. *Journal of Virology* 2005; 79(11):7095–103. https://doi.org/10.1128/JVI.79.11.7095-7103.2005 PMid: 15890949 PMCid: PMC1112131

38. Park JY, Jeong HJ, Kim JH, Kim YM, Park S-J, Kim D, et al. Diarylheptanoids from *Alnus japonica* inhibit papain-like protease of severe acute respiratory syndrome coronavirus. *Biological and Pharmaceutical Bulletin* 2012; 35(11):2036–42. https://doi.org/10.1248/bpb.b12-00623 PMid: 22971649

39. Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen K-Y. Coronaviruses — drug discovery and therapeutic options. *Nature Reviews Drug Discovery* 2016; 15(5):327–47. https://doi.org/10.1038/nrd.2015.37 PMid: 26868298 PMCID: PMC7097181

40. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003; 426(6965):450–4. https://doi.org/10.1038/nature02145 PMid: 14647384 PMCID: PMC7095016

41. Yeung K-S, Yamanaka GA, Meanwell NA. Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. *Medical Research Reviews* 2006; 26(4):414–33. https://doi.org/10.1002.med.20055 PMid: 16521129 PMCID: PMC7168515

42. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, *et al*. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. *Proceedings of the National Academy of Sciences* 2004; 101(8): 2536–41. https://doi.org/10.1073/pnas.0307140101 PMid: 14983044 PMCID: PMC356985

43. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, *et al*. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Research* 2020; 30(3):269–71. https://doi.org/10.1038/s41422-020-0282-0 PMid: 32020029 PMCID: PMC7054408

44. Multicentre collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. *Zhonghua Jie He He Hu Xi Za Zhi* 2020; 43(3):185–8.

45. Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. *Life Sciences* 2020 Mar 25; 253: 117592. https://doi.org/10.1016/j.lfs.2020.117592 PMid: 32222463 PMCID: PMC7102646

46. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, *et al*. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax* 2004; 59(3):252–6. https://doi.org/10.1136/thorax.2003.012658 PMid: 14985565 PMCID: PMC1746980

47. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, *et al*. A trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. *New England Journal of Medicine* 2020; Mar 18.

48. Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, *et al*. Teicoplanin potently blocks the cell entry of 2019-nCoV. *BioRxiv* 2020; Feb 13.
49. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents* 2020; Mar 20; 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
PMid: 32205204 PMCID: PMC7102549

50. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Research* 2020 Apr 3; 104787. https://doi.org/10.1016/j.antiviral.2020.104787
PMid: 32251768 PMCID: PMC7129059